March 9th, 2013
ACC.13 Headquarters
CardioExchange Editors, Staff
CardioExchange is dedicated to bringing you the latest from ACC.13. Check out our coverage below ─ and some of the great debates these posts have sparked ─ then tell us what you think!
News:
- Following an Embargo Break PREVAIL Trial Won’t be Presented at ACC
- HPS2-THRIVE: A ‘Disappointing But Clear’ Result
- Cangrelor During PCI May Reduce Ischemic Events
- Fibrinolysis May Benefit Late-Arriving STEMI Patients
- Eplerenone May Prevent Heart Failure in Acute STEMI Patients
- Another Negative Trial of Darbepoetin Alfa
- Was Atherosclerosis the Real Curse of the Mummy?
- Two Trials Explore On-Pump Versus Off-Pump Bypass Surgery
Analysis:
Follow our Fellows:
- The Real World Intrudes on the Start of the Meeting
- A Fellow Reflects on the Program and on her Progress from Observer to Educator
- Data Sources for Young Investigators
- New Approaches to LDL Lowering
- Great Venue, Great Sessions, but Disappointments Too
- Thinking About What Comes After Fellowship
- The Real Question About Reducing Hospital Readmissions
- You Are My Sunshine
- Learning to Network
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?